Compared with baseline (Table 2b ), there was a decreasing trend in mPAP at months 6 and 12 although no significant difference was noted (month 6, −2.60, P = 0.098, R = 0.84; month 12, −1.71, P = 0.38, R = 0.83).
← all excerpts
Potential benefit of bosentan therapy in borderline or less severe pulmonary hypertension secondary to idiopathic pulmonary fibrosis-an interim analysis of results from a prospective, single-center, randomized, parallel-group study.
1
—
—